PF-Atlas › Clinical Trials › NCT04058210

VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis Patients Heterozygous for F508del Mutation and a Minimal Function Mutation

ELX/TEZ/IVA · Not specified

Registry ID
NCT04058210
Phase
Not specified
Status
Approved For Marketing
Drug / intervention
ELX/TEZ/IVA
Sponsor
Vertex Pharmaceuticals Incorporated

About this trial

ELX/TEZ/IVA is evaluated in NCT04058210, a idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Approved For Marketing.

View NCT04058210 on ClinicalTrials.gov →

Explore related

All ELX/TEZ/IVA trialsAll IPF trials

Related trials

ELX/TEZ/IVA — NCT05153317ELX/TEZ/IVA — NCT04545515ELX/TEZ/IVA — NCT05274269ELX/TEZ/IVA — NCT03691779ELX/TEZ/IVA — NCT04702360ELX/TEZ/IVA — NCT04362761
Medical disclaimer. This page summarizes public trial data for NCT04058210 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.